US FDA approves Moderna’s Covid-19 vaccine, mNEXSPIKE

US FDA approves Moderna’s Covid-19 vaccine, mNEXSPIKE

By, Admin 2 June 2025

Moderna, Inc. has announced that the US Food and Drug Administration (FDA) has approved mNEXSPIKE (mRNA-1283), its latest Covid-19 vaccine. The vaccine is approved for adults aged 65 years and older, as well as for individuals aged 12 to 64 who have at least one underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).

 “The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from Covid-19. Covid-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.”

  • Stéphane Bancel, chief executive officer of Moderna.

Efficacy Supported by Phase 3 Clinical Trial

The FDA’s approval is based on data from a randomized, observer-blind, active-controlled phase 3 trial (NCT05815498), involving approximately 11,400 participants aged 12 and older. The primary goal was to show non-inferior vaccine efficacy compared to Moderna’s original Spikevax (mRNA-1273).

Participants received either a 10 µg dose of mRNA-1283 or a 50 µg dose of mRNA-1273. mRNA-1283 demonstrated a 9.3 percent higher relative vaccine efficacy in participants aged 12 and older and a 13.5 percent higher efficacy in adults aged 65 and older in a descriptive subgroup analysis.

Comparable Safety Profile

The safety profile of mRNA-1283 was similar to that of Spikevax, with fewer local reactions and similar systemic side effects. Commonly reported side effects included injection site pain, fatigue, headache, and myalgia.

Launch Planned for 2025–2026 Season

Moderna plans to make mNEXSPIKE available in the United States for the 2025–2026 respiratory virus season, alongside Spikevax and mRESVIA, its approved RSV vaccine. Regulatory reviews of mRNA-1283 are also ongoing in other countries.

Indication and Use

mNEXSPIKE is intended for individuals who have previously received a Covid-19 vaccine and are either:

  • 65 years of age and older, or
  • Between 12 and 64 years of age with risk factors for severe Covid-19.

While the vaccine offers protection, it may not prevent Covid-19 in all vaccinated individuals.

About Moderna

Moderna is a pioneer in the field of mRNA medicine, working to transform how diseases are treated and prevented through the advancement of mRNA technology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!